Septerna (SEPN) EPS (Weighted Average and Diluted) (2023 - 2026)
Septerna's quarterly EPS (Weighted Average and Diluted) came in at -$0.19 in Q1 2026, up 61.22% year-on-year from -$0.12 in Q1 2025, and up 20.83% quarter-over-quarter from -$0.24 in Q4 2025.
Septerna has reported EPS (Weighted Average and Diluted) for 4 years, with the latest figure at -$0.19 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 61.22% year-over-year to -$0.19; the trailing twelve-month figure through Mar 2026 stood at -$0.81 (up 38.17% YoY), and the FY2025 full-year result was -$1.1, up 84.85% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.19, up from -$0.24 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $16.78 in Q4 2023, with the low at -$8.4 in Q3 2024.
- Average EPS (Weighted Average and Diluted) over 4 years is $0.26, with a median of -$0.49 recorded in 2025.
- Peak annual rise in EPS (Weighted Average and Diluted) reached 102.14% in 2025, while the deepest fall reached 101.64% in 2025.
- Tracing SEPN's EPS (Weighted Average and Diluted) over 4 years: stood at $16.78 in 2023, then decreased by 12.93% to $14.61 in 2024, then tumbled by 101.64% to -$0.24 in 2025, then gained by 20.83% to -$0.19 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.19 (Q1 2026), -$0.24 (Q4 2025), and $0.18 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Septerna | 1.34 Bn | 1.34 Bn | - | -0.19 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.19 |
| Dec 31, 2025 | -0.24 |
| Sep 30, 2025 | 0.18 |
| Jun 30, 2025 | -0.56 |
| Mar 31, 2025 | -0.49 |
| Dec 31, 2024 | 14.61 |
| Sep 30, 2024 | -8.40 |
| Jun 30, 2024 | -7.03 |
| Mar 31, 2024 | -6.35 |
| Dec 31, 2023 | 16.78 |
| Sep 30, 2023 | -5.45 |